MARKET

ALNY

ALNY

Alnylam Pharmaceuticals Inc
NASDAQ
219.72
-11.46
-4.96%
After Hours: 219.70 -0.02 -0.01% 19:49 10/02 EDT
OPEN
231.31
PREV CLOSE
231.18
HIGH
231.36
LOW
219.40
VOLUME
1.66M
TURNOVER
--
52 WEEK HIGH
495.55
52 WEEK LOW
197.81
MARKET CAP
29.40B
P/E (TTM)
37.40
1D
5D
1M
3M
1Y
5Y
1D
Notable ETF Inflow Detected - TCAF, CNP, ALNY, KDP
NASDAQ · 1d ago
Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49%
Simply Wall St · 1d ago
Stock Market Today: S&P 500 Slips as Micron Fails to Impress, 10-Year Yields Ease to 5.25%
Benzinga · 2d ago
Alnylam Pharmaceuticals Is Maintained at Overweight by JP Morgan
Dow Jones · 3d ago
Alnylam Pharmaceuticals Price Target Cut to $369.00/Share From $375.00 by JP Morgan
Dow Jones · 3d ago
JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $369
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AxoGen (AXGN) and Biohaven Ltd. (BHVN)
TipRanks · 3d ago
Alnylam price target lowered to $369 from $375 at JPMorgan
TipRanks · 3d ago
More
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Webull offers Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ: ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.